– Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 –
–.
Adding liver metastases status to tumor sidedness may enhance first-line targeted treatment selection in certain patients with metastatic colorectal cancer.